Family Medicine & Primary Care Review

Full text

2/2026 vol. 28
Original paper

Use of anticoagulants and analgesics among hospitalized patients with COVID-19 in Kosovo

Valon Krasniqi 1, 2
,
Musa Hoxha 3
,
Genc Avdyli 4
,
Sejdi Statovci 5, 6
,
Valmira Kolshi Krasniqi 7
,
Flaka Pasha 1
,
Shaip Krasniqi 1

  1. Institute of Pharmacology with Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo

  2. Pediatrics’ Clinic, University Clinical Center of Kosovo, Prishtina, Kosovo

  3. Pulmonary Clinic, University Clinical Center of Kosovo, Prishtina, Kosovo

  4. Cardiology Clinic, University Clinical Center of Kosovo, Prishtina, Kosovo

  5. Children’s Surgery Clinic, University Clinical Center of Kosovo, Prishtina, Kosovo

  6. UBT College, Prishtina, Kosovo

  7. Department of Chemistry, Faculty of Natural and Mathematical Sciences, University of Prishtina, Prishtina, Kosovo

Family Medicine & Primary Care Review 2026; 28(2): 144–149

DOI: https://doi.org/10.5114/fmpcr.2026.161513
Data publikacji online: 2026/06/22
Article file
07 FM&PCR 2 26 - O - Krasniqi - 1804 - Anticoagulants.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Agency of Statistics of Kosovo. Population, Household and Housing Census in Kosovo 2024: Final Results Report. Prishtina: Agency of Statistics of Kosovo; 2024. Available from URL: https://ask.rks-gov.net/?utm_source.
  2. World Health Organization. Future surveillance for epidemic and pandemic diseases: a 2023 perspective. Geneva: WHO; 2023.
  3. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J 2021; 97(1147): 312–320, doi: 10.1136/postgradmedj-2020-138577.
  4. Nemati S, Nemati M, Doost M, et al. The perspectives and experiences of patients with COVID-19: a qualitative study. Fam Med Prim Care Rev 2023; 25(4): 420–426, doi: 10.5114/fmpcr.2023.132615.
  5. Paumgartten FJR, de Oliveira ACAXavier. Off label, compassionate and irrational use of medicines in COVID-19 pandemic, health consequences and ethical issues. Ciênc Saúde Coletiva 2020; 25(9), doi: 10.1590/1413-81232020259.1679202.
  6. Barnes GD, Burnett A, Allen A, et al. Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 2022; 54(2): 197–210, doi: 10.1007/s11239-022-02643-3.
  7. El-Tallawy SN, Nalamasu R, Pergolizzi JV, et al. Pain management during the COVID-19 pandemic. Pain Ther 2020; 9(2): 453–466, doi: 10.1007/s40122-020-00190-4.
  8. Zhou Q, Zhao S, Gan L, et al. Use of non-steroidal anti-inflammatory drugs and adverse outcomes during the COVID-19 pandemic: A systematic review and meta-analysis. eClinicalMedicine 2022; 46: 101373, doi: 10.1016/j.eclinm.2022.101373.
  9. Paranjpe I, Fuster V, Lala A, et al. Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. J Am Coll Cardiol 2020; 76(1): 122–124, doi: 10.1016/j.jacc.2020.05.001.
  10. Parker DG, Zentner D, Burack JA, et al. The impact of the COVID-19 pandemic on medications for opioid use disorder services in the U.S. and Canada: a scoping review. Drugs Educ Prev Policy 2023; 30(6): 529–542, doi: 10.1080/09687637.2023.2181147.
  11. Jones CM, Shoff C, Blanco C, et al. Association of receipt of opioid use disorder-related telehealth services and medications for opioid use disorder with fatal drug overdoses among medicare beneficiaries before and during the COVID-19 Pandemic. JAMA Psychiatry 2023; 80(5): 508–514, doi: 10.1001/jamapsychiatry.2023.0310.
  12. Lee D, Bergman U. Studies of Drug Utilization. In: Strom BL, Kimmel SE, Hennessy S, eds. Pharmacoepidemiology. Fifth Ed. 2012: 377–401, doi: 10.1002/9781119959946.CH24.
  13. Bergman U. The history of the Drug Utilization Research Group in Europe. Pharmacoepidemiol Drug Saf 2006; 15(2): 95–98, doi: 10.1002/PDS.1171.
  14. Hollingworth S, Kairuz T, Vaismoradi M. Measuring medicine use: Applying ATC/DDD methodology to real-world data. Pharmacy (Basel) 2021; 9(1): 60, doi: 10.3390/pharmacy9010060.
  15. WHO Collaborating Centre for Drug Statistics... [cited 17.01.2025]. Available from URL: https://scholar.google.com/scholar?hl = en&as_sdt = 0%2C5&q = WHO.+WHO+Collaborating+Centre+for+Drug+Statistics+Methodology.+Guidelines+for+ATC+classification+and+DDD+assignment+2013.+Geneva%3A+WHO%3B+2012.&btnG =.
  16. Mustafa ZU, Kow CS, Salman M, et al. Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan. Explor Res Clin Soc Pharm 2022; 5, doi: 10.1016/j.rcsop.2021.100101.
  17. Vaughn VM, Yost M, Abshireet C, et al. Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19. JAMA Netw Open 2021; 4(6): e2111788–e2111788, doi: 10.1001/jamanetworkopen.2021.11788.
  18. Le-Dang MA, Nguyen-Thi HY, Dinh LP, et al. Impact of COVID-19 on patterns of drug utilization: A case study at national hospital. PLOS ONE 2024; 19(1): e0297187, doi: 10.1371/journal.pone.0297187.
  19. Alimohamadi Y, Yekta EM, Sepandi M, et al. Hospital length of stay for COVID-19 patients: a systematic review and meta-analysis. Multidiscip Respir Med 2022; 17(1): 856, doi: 10.4081/mrm.2022.856/.
  20. Nguyen NT, Chinnid J, De Ferrante M, et al. Male gender is a predictor of higher mortality in hospitalized adults with COVID-19. PLOS ONE 2021; 16(7): e0254066, doi: 10.1371/journal.pone.0254066.
  21. Guo A, Lu J, Tanet H, et al. Risk factors on admission associated with hospital length of stay in patients with COVID-19: a retrospective cohort study. Sci Rep 2021; 11(1): 7310, doi: 10.1038/s41598-021-86853-4.
  22. Mustafa Z, Kow C, Salman M, et al. Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan. Explor Res Clin Soc 2022; 5, doi: 10.1016/j.rcsop.2021.100101.
  23. Şahin T, Ayyildiz A, Gencer-Atalay K, et al. Pain symptoms in COVID-19. Am J Phys Med Rehabil 2021; 100(4): 307–312, doi: 10.1097/PHM.0000000000001699.
  24. Valladales-Restrepo LF, Gaviria-Mendoza A, Machado-Duque ME, et al. Chronic pain and continuity of analgesic treatment during the COVID-19 pandemic. Pain Pract 2023; 23(4): 359–367, doi: 10.1111/PAPR.13197.
  25. Larrosa-García M, Garcia-Garcia S, Louro J, et al. Use of chronic medications and risk of death due to COVID-19 in hospitalised patients. Eur J Hosp Pharm 2024; 31(3): 247–252, doi: 10.1136/ejhpharm-2021-003186.
  26. WHO. Clinical management of COVID-19: living guideline, 18 August 2023 [cited 13.01.2026]. Available from URL: https://iris.who.int/bitstream/handle/10665/372288/WHO-2019-nCoV-clinical-2023.2-eng.pdf.
Copyright: © 2026 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Integrated with